{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:05:06Z","timestamp":1792292706295,"version":"4.4.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.00608","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T11:46:15Z","timestamp":1560339975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features"],"prefix":"10.3389","volume":"10","author":[{"given":"Frederike Cosima","family":"Oertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Schlie\u00dfeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander U.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00281-018-0723-8","article-title":"Sex differences in autoimmune disorders of the central nervous system","volume":"41","author":"Gold","year":"2018","journal-title":"Semin Immunopathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e869814","DOI":"10.1155\/2011\/869814","article-title":"Imaging the visual pathway in neuromyelitis optica, imaging the visual pathway in neuromyelitis optica","volume":"2011","author":"Pfueller","year":"2011","journal-title":"Mult Scler Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","author":"Chien","year":"2018","journal-title":"Mult Scler."},{"key":"B14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat Clin Pract Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1212\/NXI.0000000000000204","article-title":"Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis","volume":"3","author":"Metz","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jns.2012.06.002","article-title":"Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry","volume":"320","author":"Jarius","year":"2012","journal-title":"J Neurol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1371\/journal.pmed.0040133","article-title":"Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica","volume":"4","author":"Paul","year":"2007","journal-title":"PLoS Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnint.2016.00008","article-title":"The role of astrocytic aquaporin-4 in synaptic plasticity and learning and memory","volume":"10","author":"Szu","year":"2016","journal-title":"Front Integr Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive?","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1212\/WNL.0000000000005619","article-title":"Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder","volume":"90","author":"Hacohen","year":"2018","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00415-015-7991-1","article-title":"Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study","volume":"263","author":"Ayzenberg","year":"2016","journal-title":"J Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1212\/NXI.0000000000000188","article-title":"Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder","volume":"3","author":"Nosadini","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B48","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11481-015-9646-5","article-title":"Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID)","volume":"11","author":"Rommer","year":"2016","journal-title":"J Neuroimmune Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1474-4422(13)70089-9","article-title":"Hope for a rare disease: eculizumab in neuromyelitis optica","volume":"12","author":"Paul","year":"2013","journal-title":"Lancet Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"Mealy","year":"2017","journal-title":"Mult Scler."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1177\/1352458511431731","article-title":"A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations","volume":"18","author":"Liu","year":"2012","journal-title":"Mult Scler."},{"key":"B56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12974-016-0746-9","article-title":"Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G","volume":"13","author":"Felix","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00415-016-8138-8","article-title":"Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder","volume":"263","author":"Jeong","year":"2016","journal-title":"J Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody\u2013seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","article-title":"Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study","volume":"89","author":"Oertel","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1468-1331.2012.03867.x","article-title":"White matter volume is decreased in the brain of patients with neuromyelitis optica","volume":"20","author":"Chanson","year":"2013","journal-title":"Eur J Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1212\/NXI.0000000000000347","article-title":"Foveal thinning in neuromyelitis optica: a sign of retinal astrocytopathy?","volume":"4","author":"Yamamura","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1212\/NXI.0000000000000345","article-title":"Precision in neuroimmunology","volume":"4","author":"Dalmau","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1177\/1352458517727604","article-title":"Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD)","volume":"24","author":"Tian","year":"2017","journal-title":"Mult Scler."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1212\/NXI.0000000000000224","article-title":"Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions","volume":"3","author":"Ventura","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Mult Scler."},{"key":"B67","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1468-1331.2010.03252.x","article-title":"Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica","volume":"18","author":"Chanson","year":"2011","journal-title":"Eur J Neurol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2055217318796684","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B70","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrneurol.2017.117","article-title":"Fatigue as a symptom or comorbidity of neurological diseases","volume":"13","author":"Penner","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jns.2015.11.031","article-title":"Cognitive and psychiatric comorbidities in neuromyelitis optica","volume":"360","author":"Moore","year":"2016","journal-title":"J Neurol Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.msard.2017.10.003","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: what do we know?","volume":"18","author":"Eizaguirre","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ane.12649","article-title":"Pathology and MRI: exploring cognitive impairment in MS","volume":"134","author":"Paul","year":"2016","journal-title":"Acta Neurol Scand."},{"key":"B74","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00415-016-8345-3","article-title":"Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and meta-analysis","volume":"264","author":"Meng","year":"2017","journal-title":"J Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1590\/0004-282X20130038","article-title":"Cognitive performance of neuromyelitis optica patients: comparison with multiple sclerosis","volume":"71","author":"Vanotti","year":"2013","journal-title":"Arquivos Neuro Psiquiatr."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1177\/1352458516636246","article-title":"Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"22","author":"Kim","year":"2016","journal-title":"Mult Scler."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ensci.2017.09.001","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: a comparison of the Wechsler Adult Intelligence Scale-III and the Wechsler Memory Scale Revised with the Rao Brief Repeatable Neuropsychological Battery","volume":"9","author":"Fujimori","year":"2017","journal-title":"eNeurol Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/archneurol.2007.16","article-title":"Cognitive functions in neuromyelitis optica","volume":"65","author":"Blanc","year":"2008","journal-title":"Arch Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000002067","article-title":"Structural MRI substrates of cognitive impairment in neuromyelitis optica","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","article-title":"Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy","volume":"9","author":"Oertel","year":"2018","journal-title":"EPMA J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.neuint.2013.05.003","article-title":"Aquaporin-4 water channels and synaptic plasticity in the hippocampus","volume":"63","author":"Scharfman","year":"2013","journal-title":"Neurochem Int."},{"key":"B84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00429-011-0373-2","article-title":"Aquaporin-4 promotes memory consolidation in Morris water maze","volume":"218","author":"Fan","year":"2013","journal-title":"Brain Struct Funct."},{"key":"B85","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ene.13224","article-title":"Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"24","author":"Hyun","year":"2017","journal-title":"Eur J Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1523\/JNEUROSCI.6249-10.2011","article-title":"Impairment of select forms of spatial memory and neurotrophin-dependent synaptic plasticity by deletion of glial aquaporin-4","volume":"31","author":"Skucas","year":"2011","journal-title":"J Neurosci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00281-015-0515-3","article-title":"Control of autoimmune CNS inflammation by astrocytes","volume":"37","author":"Rothhammer","year":"2015","journal-title":"Semin Immunopathol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.brainresbull.2017.02.011","article-title":"The role of aquaporin-4 in synaptic plasticity, memory and disease","volume":"136","author":"Hubbard","year":"2018","journal-title":"Brain Res Bull."},{"key":"B89","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/00207454.2011.608456","article-title":"Cognitive function, depression, fatigue, and activities of daily living in patients with neuromyelitis optica after acute relapse","volume":"121","author":"He","year":"2011","journal-title":"Int J Neurosci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/cns.12411","article-title":"Hypoxemia, sleep disturbances, and depression correlated with fatigue in neuromyelitis optica spectrum disorder","volume":"21","author":"Pan","year":"2015","journal-title":"CNS Neurosci Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e0177230","DOI":"10.1371\/journal.pone.0177230","article-title":"Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life","volume":"12","author":"Seok","year":"2017","journal-title":"PLoS ONE."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1212\/NXI.0000000000000387","article-title":"MRI evaluation of thalamic volume differentiates MS from common mimics","volume":"4","author":"Solomon","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00330-016-4282-x","article-title":"Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study","volume":"26","author":"Pache","year":"2016","journal-title":"Eur Radiol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1212\/NXI.0000000000000102","article-title":"Early CNS neurodegeneration in radiologically isolated syndrome","volume":"2","author":"Azevedo","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B95","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1352458514551452","article-title":"Focal demyelinative damage and neighboring white matter integrity: an optic neuritis study","volume":"21","author":"Raz","year":"2015","journal-title":"Mult Scler."},{"key":"B96","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaneurol.2015.0248","article-title":"Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder","volume":"72","author":"Kremer","year":"2015","journal-title":"JAMA Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1212\/NXI.0000000000000399","article-title":"Loss of corticospinal tract integrity in early MS disease stages","volume":"4","author":"Pawlitzki","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1212\/NXI.0000000000000259","article-title":"MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T","volume":"3","author":"Sinnecker","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"398259","DOI":"10.1155\/2013\/398259","article-title":"Ultrahigh-field MR (7 T) imaging of brain lesions in neuromyelitis optica","volume":"2013","author":"Kister","year":"2013","journal-title":"Mult Scler Int."},{"key":"B102","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrneurol.2018.14","article-title":"The current role of MRI in differentiating multiple sclerosis from its imaging mimics","volume":"14","author":"Geraldes","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1001\/archneurol.2011.249","article-title":"Brain involvement in neuromyelitis optica spectrum disorders","volume":"68","author":"Chan","year":"2011","journal-title":"Arch Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1212\/WNL.0b013e3182648bc8","article-title":"Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis","volume":"79","author":"Sinnecker","year":"2012","journal-title":"Neurology."},{"key":"B106","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B107","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jurynczyk","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B108","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur J Neurol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody\u2013positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s13167-017-0102-x","article-title":"Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system","volume":"8","author":"Kuchling","year":"2017","journal-title":"EPMA J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1212\/NXI.0000000000000229","article-title":"Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD","volume":"3","author":"Finke","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1177\/1352458513519838","article-title":"Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders","volume":"20","author":"von Glehn","year":"2014","journal-title":"Mult Scler."},{"key":"B114","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamaneurol.2017.3890","article-title":"Association of visual impairment in neuromyelitis optica spectrum disorder with visual network reorganization","volume":"75","author":"Finke","year":"2018","journal-title":"JAMA Neurol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e0184012","DOI":"10.1371\/journal.pone.0184012","article-title":"Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"12","author":"Masuda","year":"2017","journal-title":"PLoS ONE."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e33878","DOI":"10.1371\/journal.pone.0033878","article-title":"White matter atrophy and cognitive dysfunctions in neuromyelitis optica","volume":"7","author":"Blanc","year":"2012","journal-title":"PLoS ONE."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320249","article-title":"Selective, attack-related volume loss of thalamic nuclei in Neuromyelitis Optica Spectrum Disorders","author":"Papadopoulou","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3389\/fneur.2018.01104","article-title":"White matter network disruption and cognitive dysfunction in neuromyelitis optica spectrum disorder","volume":"9","author":"Cho","year":"2018","journal-title":"Front Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e48846","DOI":"10.1371\/journal.pone.0048846","article-title":"Altered topological organization of white matter structural networks in patients with neuromyelitis optica","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T14:00:03Z","timestamp":1560520803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":119,"alternative-id":["10.3389\/fneur.2019.00608"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.00608","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,12]]},"article-number":"608"}}